Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Return on Invested Capital (2017 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Return on Invested Capital for 13 consecutive years, with 0.94% as the latest value for Q2 2025.

  • Quarterly Return on Invested Capital fell 59.0% to 0.94% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 0.94% through Jun 2025, down 59.0% year-over-year, with the annual reading at 0.61% for FY2025, 8.0% down from the prior year.
  • Return on Invested Capital hit 0.94% in Q2 2025 for Vistagen Therapeutics, down from 0.74% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.19% in Q1 2021 to a low of 4.91% in Q2 2023.
  • Historically, Return on Invested Capital has averaged 1.18% across 5 years, with a median of 0.63% in 2024.
  • Biggest five-year swings in Return on Invested Capital: crashed -2291bps in 2021 and later skyrocketed 456bps in 2024.
  • Year by year, Return on Invested Capital stood at 0.46% in 2021, then tumbled by -446bps to 2.53% in 2022, then skyrocketed by 83bps to 0.43% in 2023, then crashed by -42bps to 0.61% in 2024, then crashed by -55bps to 0.94% in 2025.
  • Business Quant data shows Return on Invested Capital for VTGN at 0.94% in Q2 2025, 0.74% in Q1 2025, and 0.61% in Q4 2024.